A Prospective Observational Post-Marketing Study of Harvoni in Japanese Patients With Genotype 1 Chronic Hepatitis C Infection
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Gilead Sciences
- 22 Feb 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Oct 2016 Planned End Date changed from 1 Jul 2018 to 1 Sep 2017.
- 10 Oct 2016 Planned primary completion date changed from 1 Jul 2018 to 1 Sep 2017.